Comment on "Neoadjuvant systemic therapy in patients undergoing nephroureterectomy for urothelial cancer: a multidisciplinary systematic review and critical analysis" on behalf of the Young Academic Urologists - Urothelial Cancer Working Group
Minerva Urol Nephrol
.
2022 Dec;74(6):813-815.
doi: 10.23736/S2724-6051.22.05181-3.
Authors
Luca Afferi
1
,
Andrea Gallioli
2
,
Francesco Del Giudice
3
,
Benjamin Pradere
4
,
Francesco Soria
5
,
Marco Moschini
6
Affiliations
1
Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland - luca.afferi@luks.ch.
2
Department of Urology, Puigvert Foundation, Universitat Autònoma de Barcelona, Barcelona, Spain.
3
Department of Maternal Infant and Urological Sciences, Umberto I Polyclinic Hospital, Sapienza University, Rome, Italy.
4
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
5
Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Turin, Turin, Italy.
6
Department of Urology, Urological Research Institute, San Raffaele Scientific Institute, Milan, Italy.
PMID:
36629814
DOI:
10.23736/S2724-6051.22.05181-3
No abstract available
Publication types
Letter
Comment
MeSH terms
Carcinoma, Transitional Cell* / drug therapy
Carcinoma, Transitional Cell* / surgery
Humans
Neoadjuvant Therapy*
Nephroureterectomy*
Urologic Neoplasms* / drug therapy
Urologic Neoplasms* / surgery